CD4 and cancer: We show here for the first time that patients with multiple indications of advanced cancer had higher activation markers involved in immune checkpoint pathways in CD4+ and CD8+ T cells, several higher suppressive Treg and MDSC subsets, and altered expression of PD-L1 on APCs (Figure 5).